Stock ATNM ACTINIUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Actinium Pharmaceuticals, Inc. Stock

Equities

ATNM

US00507W2061

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
7.06 USD +2.10% Intraday chart for Actinium Pharmaceuticals, Inc. -2.62% +38.98%
Apr. 18 Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting CI
Apr. 01 Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting CI

Financials (USD)

Sales 2024 * 189K Sales 2025 * 69.3M Capitalization 208M
Net income 2024 * -59M Net income 2025 * -2M EV / Sales 2024 * 1,058 x
Net cash position 2024 * 7.22M Net cash position 2025 * - EV / Sales 2025 * 2.99 x
P/E ratio 2024 *
-3.77 x
P/E ratio 2025 *
-41.1 x
Employees 49
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.84%
More Fundamentals * Assessed data

Chart Actinium Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting CI
Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting CI
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy CI
Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating MT
B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating MT
Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition CI
Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer CI
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting CI
National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc CI
HSBC Starts Actinium Pharmaceuticals With Buy Rating, Price Target is $11.60 MT
HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $50 From $53, Keeps Buy Rating MT
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) added to Russell Small Cap Comp Value Index CI
More news

Analyst Recommendations on Actinium Pharmaceuticals, Inc.

Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating MT
B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating MT
HSBC Starts Actinium Pharmaceuticals With Buy Rating, Price Target is $11.60 MT
HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $50 From $53, Keeps Buy Rating MT
B. Riley Raises Actinium Pharmaceuticals' Price Target to $20 From $18, Keeps Buy Rating MT
More recommendations

Press releases Actinium Pharmaceuticals, Inc.

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML AQ
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest AQ
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation AQ
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations AQ
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey AQ
More press releases

Quotes and Performance

1 day+2.10%
1 week-2.62%
Current month-9.83%
1 month-23.26%
3 months+38.70%
6 months+30.74%
Current year+38.98%
More quotes

Highs and lows

1 week
6.60
Extreme 6.6
7.43
1 month
6.60
Extreme 6.6
9.68
Current year
4.80
Extreme 4.8
9.86
1 year
4.00
Extreme 4
9.86
3 years
4.00
Extreme 4
15.12
5 years
4.00
Extreme 4
19.47
10 years
4.00
Extreme 4
411.00
More quotes

Managers and Directors - Actinium Pharmaceuticals, Inc.

Managers TitleAgeSince
Sandesh Seth CEO
 Chief Executive Officer 60 12-02-29
Steve O'Loughlin DFI
 Director of Finance/CFO 39 15-10-12
Akash Nahar CTO
 Chief Tech/Sci/R&D Officer - 22-10-26
Members of the board TitleAgeSince
Richard Steinhart BRD
 Director/Board Member 66 13-11-07
C. Nicholson BRD
 Director/Board Member 68 07-12-31
Ajit Shetty BRD
 Director/Board Member 77 17-03-27
More insiders

ETFs positioned on Actinium Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.02% 0 M€ 0.00% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.35% -
More ETFs positioned on Actinium Pharmaceuticals, Inc.

Quotes

Date Price Change Volume
24-04-24 7.06 +1.44% 153,433
24-04-23 6.96 -2.93% 185,256
24-04-22 7.17 +4.67% 192,609
24-04-19 6.85 +2.70% 347,635
24-04-18 6.67 -8.00% 420,871

Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT

More quotes

Company Profile

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Sector
Biotechnology & Medical Research
Calendar
2025-03-13 - Q4 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Ratings for Actinium Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.06 USD
Average target price
25.47 USD
Spread / Average Target
+260.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTINIUM PHARMACEUTICALS, INC. Stock Actinium Pharmaceuticals, Inc.
+38.98% 208M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+1.69% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-9.16% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATNM Stock